Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EBITDA (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed EBITDA for 5 consecutive years, with -$15.2 million as the latest value for Q4 2025.

  • For Q4 2025, EBITDA rose 29.68% year-over-year to -$15.2 million; the TTM value through Dec 2025 reached -$59.1 million, up 34.76%, while the annual FY2025 figure was -$59.1 million, 34.76% up from the prior year.
  • EBITDA hit -$15.2 million in Q4 2025 for Kezar Life Sciences, down from -$11.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$11.7 million in Q3 2025 and bottomed at -$34.6 million in Q4 2023.
  • Average EBITDA over 5 years is -$19.3 million, with a median of -$18.3 million recorded in 2022.
  • Year-over-year, EBITDA tumbled 72.65% in 2023 and then soared 46.62% in 2025.
  • Kezar Life Sciences' EBITDA stood at -$14.1 million in 2021, then crashed by 42.05% to -$20.0 million in 2022, then crashed by 72.65% to -$34.6 million in 2023, then skyrocketed by 37.66% to -$21.6 million in 2024, then grew by 29.68% to -$15.2 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$15.2 million, -$11.7 million, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.